	US 11,857,531 B2
	Combination mast cell inhibition for treatment of BPH/LUTS
Praveen Thumbikat, Chicago, IL (US); and Anthony J. Schaeffer, Hinsdale, IL (US)
Assigned to Northwestern University, Evanston, IL (US)
Filed by Northwestern University, Evanston, IL (US)
Filed on Aug. 5, 2021, as Appl. No. 17/395,153.
Claims priority of provisional application 63/173,050, filed on Apr. 9, 2021.
Claims priority of provisional application 63/061,312, filed on Aug. 5, 2020.
Prior Publication US 2022/0040143 A1, Feb. 10, 2022
Int. Cl. A61K 31/352 (2006.01); A61P 13/08 (2006.01); A61K 31/495 (2006.01)

CPC A61K 31/352 (2013.01) [A61K 31/495 (2013.01); A61P 13/08 (2018.01)]

3 Claims

1. A method of treating benign prostatic hyperplasia (BPH) in a subject, comprising providing to the subject one or more inhibitors of mast cell function, wherein the one or more inhibitors of mast cell function comprise cromolyn sodium cetirizine.